This Month in Psychopharmacology

THIS MONTH IN
PSYCHOPHARMACOLOGY

Positive Topline Results for Novel Autism Drug
March 1, 2021

Autism spectrum disorder can be highly debilitating with issues in communication, socialization, and repetitive behaviors. Unfortunately, there is little available in the way of treatment. Exciting results from a Phase II clinical study conducted by...

Continue reading (Members only)

FDA Authorizes Marketing For Daytime Treatment For Obstructive Sleep Apnea
February 28, 2021

The U.S. Food and Drug Administration has approved the first daytime electrical stimulation device for the treatment of obstructive sleep apnea. The device strengthens tongue muscles through electrical stimulation, and...

Continue reading (Members only)

Histamine 3 Receptor Inverse Agonist For Cognitive Disorders
February 26, 2021

istamine H3 receptors, found throughout the cortex and hippocampus, have been hypothesized to be involved with cognition, learning, and memory. Several preclinical animal model studies have shown that H3 receptor antagonists/inverse agonists may have procognitive effects; however...

Continue reading (Members only)

Switching Antipsychotics to Ameliorate Weight Gain
February 23, 2021

Atypical antipsychotics are often associated with detrimental metabolic changes that may influence treatment adherence, quality of life, and mortality. In this meta-analysis, the authors investigated the benefits of switching from one antipsychotic to another with less propensity for metabolic changes...

Aggression Reactivity in Depression May Signal Risk for Converting to Bipolar Disorder
February 20, 2021

Identifying factors that predict conversion from depression to bipolar disorder may be useful for early recognition and appropriate treatment of bipolar disorder. The current study examined 1) whether anger, measured cross-sectionally, differed in patients who converted to bipolar disorder compared to patients with remitted or current unipolar depression; and..

Continue reading (Members only)

Methamphetamine Overdose Deaths in the US by Sex and Race and Ethnicity
February 17, 2021

Rates of drug overdose involving methamphetamine have increased tremendously in the past decade. Work by Han and colleagues explored the extent to which methamphetamine overdose death rates in the United States (US) differed as a function of sex, race, and ethnicity using...

Continue reading (Members only)

Alarming Association of Psychiatric Disorders and Mortality Among COVID-19 Patients
February 15, 2021

In a recent cohort study of 7348 adults with laboratory-confirmed COVID-19 in a New York health system, a schizophrenia spectrum diagnosis was associated with an increased risk of death after adjusting for medical and demographic risk factors. The patients were followed for...

Continue reading (Members only)

Clozapine to Reduce Aggression in Patients With Schizophrenia and Conduct Disorder
February 11, 2021

The first head-to-head comparison study of clozapine, olanzapine, and haloperidol in the treatment of violent schizophrenia patients with and without conduct disorder was recently conducted. Patients who had a history of being physically assaultive...

Continue reading (Members only)

Scale May Detect More Than Depression in Early Pregnancy
February 8, 2021

Postpartum depression continues to be prevalent, while early detection methods can help prevent this mental health condition. In a recent study, 2,271 antenatal women participated in a study that tested the efficacy of the Edinburgh Postnatal Depression Scale...

Buprenorphine for Meth Addiction?
February 4, 2021

Methamphetamine use disorder is a growing problem across the United States and the world. Unlike with opioid use disorder, there is currently no pharmacological treatment or medication assisted therapy for methamphetamine abuse. For methamphetamine use disorder, treatment is...

Top of Page